17-N-Allylamino-17-demethoxygeldanamycin
From Wikipedia, the free encyclopedia
(Redirected from 17-N-allylamino-17-demethoxygeldanamycin)
| 17-N-Allylamino-17-demethoxygeldanamycin | |
|---|---|
 |
|
| IUPAC name |
[(3S,5S,6R,7S,8E,10R,11S,12E,14E)-21-
(allylamino)-6-hydroxy-5,11-dimethoxy-3, 7,9,15-tetramethyl-16,20,22-trioxo-17- azabicyclo[16.3.1]docosa-8,12,14,18,21- pentaen-10-yl] carbamate |
| Identifiers | |
| CAS number | 75747-14-7 |
| PubChem | 6440175 |
| SMILES |
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC
(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC |
| ChemSpider ID | 21106220 |
| Properties | |
| Molecular formula | C31H43N3O8 |
| Molar mass | 585.689 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. It works by targeting Hsp90, which is expressed in those tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.
[edit] References
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (September 2007) |
[edit] External links
- Phase 1 trial
- Another Phase 1 trial
- National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
- Safety sheet for 17AAG
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
 |
This article about an organic compound is a stub. You can help Wikipedia by expanding it. |
